Quickfind
Show latest about:
Sector
Topic
Keep settings
  Freetext search
 Home
 News
 Analysis
 Features
 Market prices
 Technology guide
 Real estate
 Israel in depth
RSS  feeds
  Search results
News
Mylan shareholders approve Perrigo takeover bid
65% of Mylan's shareholders approved the $30 billion takeover bid for Perrigo.
Globes correspondent   28 Aug 15   17:37

Macrocure share price plunges after trial failure
The Phase III clinical trial for CureXcell for treatment of venous leg ulcers is not expected to meet its main target.
Shiri Habib-Valdhorn   23 Aug 15   16:03

UBS: Copaxone sales strong despite generic rivals
UBS says, "The launch for generic Copaxone has not gone very well, with molecule share hovering around 5%."
Shiri Habib-Valdhorn   20 Aug 15   15:14

Teva to oppose Mylan's bid to take over Perrigo
Teva has a 4.6% stake in Mylan and has lost $370 million on paper on its holdings in its rival.
Shiri Habib-Valdhorn   18 Aug 15   19:16

Features
MeMed swiftly diagnoses if a disease is viral or bacterial
The Israeli company's innovative diagnostic solutions reduce use of unnecessary antibiotics.
Chen Shalita   19 Aug 15   16:14

Teva torn between two very different types of drugs
Teva is faced with an identity crisis: generic or branded pharmaceutical company? IBI VP Elah Alkalay discusses the challenges.
Elah Alkalay    5 Aug 15   11:21

Israeli company offers new hope for treating severe depression
NeuroRX, run by brothers Jonathan and Daniel Javitt, is based on research spurred by a close friend's suicide.
Gali Weinreb    1 Jul 15   16:16

For more results from our archive, Click here.